Close Close
Popular Financial Topics Discover relevant content from across the suite of ALM legal publications From the Industry More content from ThinkAdvisor and select sponsors Investment Advisor Issue Gallery Read digital editions of Investment Advisor Magazine Tax Facts Get clear, current, and reliable answers to pressing tax questions
Luminaries Awards

Life Health > Health Insurance > Health Insurance

"Doughnut hole" discourages drug use

Your article was successfully shared with the contacts you provided.

Some 18,000 Medicare beneficiaries could discontinue their prescribed medications for lack of funds, a new study finds. The Brigham and Women’s Hospital study, led by Jennifer Polinsky, found that most Medicare and Medicaid patients chose not to switch to generic or other cheaper alternative drugs, despite being advised to do so by those programs.

Researchers looked at the effect of government drug policy on medication use for 663,850 Medicare beneficiaries beginning in 2006. Medicare Part D was introduced in 2006, but because of the coverage “doughnut hole,” patients must pay 100 percent once they have accumulated $2,830 in drug costs. Three to four million beneficiaries fell into the hole from 2006 to 2010, when the health reform law reduced that burden.

While the study did not examine the effect of the doughnut hole on patient outcomes, there is reason to believe that beneficiaries’ discontinuation of their prescribed medications has had a negative effect on health. “Blunt cost-containment features such as the coverage gap have an adverse impact on drug utilization that may conceivably affect health outcomes,” said Polinsky in the Public Library of Science journal that featured the study.

Researchers recommended that government programs employ a strategy that promotes the use of drugs that offer high benefit for a low cost to improve outcomes for Medicare beneficiaries.

For more seniors and medications, see:


© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.